These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18472982)

  • 1. Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection.
    Chae HB; Hann HW
    Ther Clin Risk Manag; 2007 Aug; 3(4):605-12. PubMed ID: 18472982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
    Rapti I; Hadziyannis S
    World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
    Martin P; Lau DT; Nguyen MH; Janssen HL; Dieterich DT; Peters MG; Jacobson IM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2071-87.e16. PubMed ID: 26188135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of chronic hepatitis B.
    Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
    Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Hadziyannis SJ
    Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
    Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
    Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of chronic hepatitis B virus infection: a new era of disease control.
    Farrell GC; Teoh NC
    Intern Med J; 2006 Feb; 36(2):100-13. PubMed ID: 16472264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
    Chen LP; Zhao J; Du Y; Han YF; Su T; Zhang HW; Cao GW
    World J Virol; 2012 Dec; 1(6):174-83. PubMed ID: 24175223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Hepatitis B Infection: A Review.
    Tang LSY; Covert E; Wilson E; Kottilil S
    JAMA; 2018 May; 319(17):1802-1813. PubMed ID: 29715359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Arnold E; Yuan Y; Iloeje U; Cook G
    Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B.
    Tziomalos K
    World J Hepatol; 2010 Mar; 2(3):91-3. PubMed ID: 21160979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.